NATH BIOGENES (INDIA)
Back to Income Statement
|
NATH BIOGENES (INDIA) Last 5 Year Revenue History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2013 | Mar2012 | |
---|---|---|---|---|---|
Net Sales | ₹301 Cr | ₹278 Cr | ₹13,770,298 Cr | ₹124 Cr | ₹124 Cr |
What is the latest Revenue of NATH BIOGENES (INDIA) ?
Year | Revenue |
---|---|
Mar2024 | ₹301 Cr |
Mar2023 | ₹278 Cr |
Mar2022 | ₹13,770,298 Cr |
Mar2013 | ₹124 Cr |
Mar2012 | ₹124 Cr |
How is Revenue of NATH BIOGENES (INDIA) Trending?
Years | Revenue | % Change | |
---|---|---|---|
Mar2024 | ₹301 Cr | 8.26 | |
Mar2023 | ₹278 Cr | -100.00 | |
Mar2022 | ₹13,770,298 Cr | 11,112,596.80 | |
Mar2013 | ₹124 Cr | 0.00 | |
Mar2012 | ₹124 Cr | - |
Compare Revenue of peers of NATH BIOGENES (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATH BIOGENES (INDIA) | ₹286.3 Cr | -6.4% | -10.1% | -25% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹11,592.2 Cr | -9.5% | -21.2% | -0.4% | Stock Analytics | |
KAVERI SEED COMPANY | ₹5,148.0 Cr | 2.1% | 11% | 55.9% | Stock Analytics | |
VENKYS (INDIA) | ₹2,301.8 Cr | -1.3% | -9.9% | -9.1% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,405.4 Cr | -7% | -12.6% | -38.5% | Stock Analytics | |
INDO US BIOTECH | ₹394.8 Cr | -9.8% | -10.3% | -14.4% | Stock Analytics |
NATH BIOGENES (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATH BIOGENES (INDIA) | -6.4% |
-10.1% |
-25% |
SENSEX | -3.4% |
-4.4% |
0.6% |
You may also like the below Video Courses